Evaluation and classification of severity for 176 genes on an expanded carrier screening panel

Aishwarya Arjunan, MS, MPH, CGC[1†], Holly Bellerose, MS, CGC[1], Raul Torres, PhD[1], Rotem Ben-Shachar, PhD[1], Jodi D. Hoffman, MD[2], Brad Angle, MD[3], Robert Nathan Slotnick, MD[4], Brittany N. Simpson, MD[5], Andrea M. Lewis, MS, CGC[6,7], Pilar L. Magoulas, MS, CGC[6,7], Kelly Bontempo, MS, CGC[3], Jeanine Schulze, MS, CCG[8], Jennifer Tarpinian, MS, CGC[9,‡,], Jessica A Bucher, MS, CGC[3], Richard Dineen, MS, CGC[10], Allison Goetsch, MS, CGC[11,12], Gabriel A. Lazarin, MS, CGC[1‡§], Katherine Johansen Taber, PhD[1§]

1. Myriad Women's Health, 180 Kimball Way, South San Francisco, CA, USA
2. Boston University School of Medicine, 850 Harrison Ave, Boston, MA, USA
3. Advocate Children's Hospital, 1875 Dempster Street, Park Ridge, IL, USA
4. Renown Health Cancer Institute, 6502 S McCarran Blvd, Reno, NV, USA
5. Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, USA
6. Baylor College of Medicine, One Baylor Plaza, Houston TX, USA
7. Texas Children's Hospital, 6701 Fannin Street, Houston TX, USA
8. Indiana University School of Medicine, 410 West 10th St, Indianapolis, IN, USA
9. Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA, USA
10. Rush University Medical Center, 1653 W Congress Parkway, Chicago, IL, USA
11. Ann and Robert H. Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Chicago, IL USA
12. Feinberg School of Medicine, Northwestern University, 420 E Superior St, Chicago, IL USA

[†]Author for correspondence: mwh_research@myriad.com
[‡]JT was an employee of Children's Hospital of Philadelphia at the time of study and has since become an employee of Myriad Women's Health. GAL was an employee of Myriad Women's Health at the time of study.
[§]GAL and KJT contributed equally

Conflict of Interest Statement

Funding Statement

This study was funded by Myriad Genetics.

What's already known about this topic?

- Disease severity is an important consideration for disease inclusion on expanded carrier screening panels.
- An algorithm that objectively classifies diseases into severity categories has been published and validated.

What does this study add?

- 176 genes were classified into severity categories.
- The algorithm was used to bring clarity to American College of Obstetricians and Gynecologist's (ACOG's) severity criteria that are not easily interpretable.
- 170 of 176 genes met at least one of ACOG's severity criteria.

Data Availability Statement

The data that support the findings of this study have been completely reported in this manuscript and shared in the Figures and Supplementary Material.

Abstract

Background

Severity is an important factor for inclusion of diseases on expanded carrier screening (ECS) panels. Here, we applied a validated algorithm that objectively classifies diseases into severity categories to 176 genes on a clinically available ECS panel. We then mapped disease traits from the algorithm to severity-related criteria cited by the American College of Obstetricians and Gynecologists (ACOG).

Methods

Eight genetic counselors (GCs), followed by four medical geneticists (MDs), applied the algorithm to subsets of the 176 genes. MDs and GCs then determined which disease traits met ACOG severity criteria.

Results

Upon initial GC and MD review, 107/176 genes (61%) and 133/176 genes (76%), respectively, had concordant classifications, with consensus reached for all genes. Final severity classifications were 68 (39%) profound, 71 (40%) severe, 36 (20%) moderate, and one (1%) mild. The vast majority of genes (170 out of 176) met at least one of ACOG's four severity criteria.

Conclusion

This study classified the severity of a large set of Mendelian genes by collaborative clinical expert application of an algorithm. Further, it clarified and operationalized difficult to interpret ACOG severity criteria via mapping of disease traits, thereby promoting consistency of ACOG criteria interpretation across laboratories.

Keywords

Disease severity, expanded carrier screening, genetic condition taxonomy, rare disease, ECS

Introduction

Carrier screening identifies couples at risk of having offspring affected by a genetic disease, thereby informing reproductive decision-making and pregnancy management. Expanded carrier screening (ECS) accomplishes this for dozens to hundreds of diseases, in comparison to traditional ethnicity-based screening approaches meant to detect a limited number of conditions prevalent within those ethnic groups (1). The American College of Obstetricians and Gynecologists (ACOG) considers ECS to be an acceptable screening strategy and has proposed that conditions selected for screening panels should meet several of seven criteria for disease inclusion on ECS panels (2). Four of these criteria address disease severity, stating that conditions should: 1. have a detrimental effect on quality of life, 2. cause cognitive or physical impairment, 3. have an onset early in life, or 4. require surgical or medical intervention (2). Similarly, the American College of Medical Genetics and Genomics (ACMG) position statement on ECS states that "disorders should be of a nature that most at-risk patients and their partners identified in the screening program would consider having prenatal diagnosis to facilitate making decisions around reproduction" (3). However, individuals have varying perceptions of the concept of severity based on their valuation of phenotypic traits (4, 5).

Disease severity inclusion criteria for ECS panels have not been widely studied. However, multiple studies have shown that disease categorization is helpful for patients in understanding the types of diseases included on ECS panels, and facilitates reproductive decision-making (5-7). In 2014, Lazarin et al. published an algorithm to objectively categorize disease severity (4). In the study, 192 health care providers rated 13 individual disease traits related to disease severity, independent of any named genetic disease. Disease traits (e.g., shortened lifespan, intellectual disability), as opposed to diseases themselves, were evaluated. This is because, despite health care providers' potential lack of familiarity with many rare genetic diseases, the traits associated with them are often encountered by health care providers regardless of the

etiology. The analysis established and validated an algorithm that can be applied to a disease,

with its given set of individual phenotypic traits, resulting in a classification of the condition into

one of four severity categories: profound, severe, moderate, and mild (4).

To date, no published studies have rigorously applied the algorithm using health care providers

with specialized knowledge of genetic disease, nor has it been applied to the large number of

diseases currently included on many ECS panels. In this study, we aimed to assign an objective

severity classification to 176 genetic diseases in order to inform consideration of their inclusion

on ECS panels. We engaged board-certified pediatric genetic counselors and medical

geneticists in clinical practice who have experience treating patients affected with conditions

commonly found on ECS panels. Furthermore, we mapped disease traits defining the

algorithm's severity categories to ACOG's four severity criteria in order to provide objective

definitions of the criteria.

Materials and Methods

Institutional Review Board Considerations

This study did not use patient samples or results and therefore was not subject to review by an

institutional review board or ethics committee.

Gene Classifications

Eight pediatric genetic counselors (GCs) followed by four medical geneticists (MDs) applied a

validated severity algorithm (4) to randomly assigned subsets of 176 genes offered on a

commercially available ECS panel (Foresight, Myriad Women's Health). The algorithm was

applied to *genes*, rather than *diseases*, because some conditions are caused by multiple genes

(e.g. Usher Syndrome, Fanconi Anemia, Niemann Pick Disease) and some genes are

associated with multiple conditions (e.g. *HBB, FKTN, MYO7A)*. The algorithm (described in

Figure 1) was applied in a two-step review and consensus process as described in Figure 2 and

Supplementary Text S1. Honoraria were provided to each GC and MD participant. Permutation

testing was conducted to determine whether particular individuals within each GC (1-4) or MD

(1-2) pair consistently classified disease genes as higher or lower in severity than their

counterpart (see Supplementary Text S2).

Mapping Disease Traits to ACOG criteria

Following GC and MD gene classifications, each disease trait assessed in the algorithm (see

Figure 1) was mapped collaboratively by the MDs and GCs to the four ACOG severity criteria: 1.

a detrimental effect on quality of life, 2. cognitive or physical impairment, 3. onset early in life,

and 4. requires surgical or medical intervention. Disease traits were mapped to ACOG severity

criteria only if all GCs and MDs assessing each gene agreed on the traits. To assess ACOG's

"detrimental effect on quality of life" criterion, we considered "quality of life" to be defined by the

domains included in the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales

(physical functioning, emotional functioning, social functioning, and school functioning) (8) and

PedsQL Infant Scales (physical functioning, physical symptoms, emotional functioning, social

functioning, and cognitive functioning) (9). Disease traits that negatively impact these PedsQL

domains were then mapped to the "detrimental effect on quality of life" criterion. We considered

ACOG's "cause cognitive or physical impairment" criterion to be captured by the PedsQL

Generic Core and Infant Scales domains of physical functioning and physical symptoms

(physical impairment) and school functioning and cognitive functioning (cognitive impairment)

(8, 9). To interpret ACOG's "onset early in life" criterion, we used the American Academy of

Pediatrics' (AAP) definitions of infancy (birth to age 2 years of age), childhood (2-12 years of

age), and adolescence (12-21 years of age) (10). Though the severity algorithm uses shortened

lifespan as a disease trait rather than age of onset, we reasoned that a condition that results in

death before the end of adolescence (age 21 years) would be considered "early onset." Thus, to

simplify the mapping, tier 1 traits of "shortened life span: infancy" and "shortened life span:

childhood/adolescence" were combined into one trait. We interpreted "require surgical or

medical intervention" as only interventions that are delivered within the context of the health

care setting and that are required to treat, delay, halt the onset of, or lessen the severity of

disease symptoms.

Data Analysis

Descriptive statistics were used to characterize general data trends. Statistical significance

between proportions was determined using chi-squared analysis; a result was considered

significant when $p < 0.05$.

Results

Genetic Counselor Review and Classification

After initial review across all GC pairs, 107 of the 176 disease-associated genes (60.8%) had

concordant severity classifications (Figure 3A, Table 1). Within the four GC pairs, concordances

were 68.2% (30/44 genes), 47.7% (21/44 genes), 65.9% (29/44 genes), and 61.4% (27/44

genes), respectively (Figure 3A, Table 1). With the exception of four genes (*NR0B1, ABCC8,*

KCNJ11, CYP21A2), all discordant classifications were within one level of classification (Figure

3A, Table 1). A permutation test was conducted to determine whether any individual within each

GC pair tended to classify genes as more or less severe than their counterpart and found no

significant difference (all $p > 0.05$; Supplementary Figure 1). Reasons for discordances noted by

the GC pairs included difficulties in determining the primary phenotype associated with a

specific disease with varying severity, difficulty discerning the level of intellectual disability

associated with the disease from the available literature, and inability to locate published data

regarding life expectancies and phenotypic differences in various forms of the conditions. After

final review of discordances and consensus on final classifications between each GC pair, 65

genes (36.9%) were categorized as profound, 65 (36.9%) as severe, 42 (23.9%) as moderate,

and four (2.3%) as mild (Table 1).

Medical Geneticist Review and Classification

After initial review across both MD pairs, 133 of the 176 disease-associated genes (76%) had

concordant classifications (Figure 3B, Table 1). Within each MD pair, concordances were 84.1%

(74/88 genes, MD Pair 1) and 67% (59/88 genes, MD Pair 2) (Figure 3B, Table 1). One member

of MD Pair 1 did not definitively classify five genes; these were considered discordances. All but

one discordant classification (*SLC22A5*) were within one level of classification (Figure 3B, Table

1). A permutation test was conducted (similar to that for GCs) to determine whether any

individual within each MD pair tended to classify genes as more or less severe than their

counterpart and found no significant difference (all $p > 0.05$; Supplementary Figure 1). Reasons

for discordances included no definitive classification, multiple phenotypes associated with the

gene, unknown percentages of individuals with intellectual disability or shortened lifespan, and

difficulties in determining life expectancy in the untreated state for conditions for which treatment

is available. After final MD review of discordances and consensus on final classifications, 68

(38.6%) genes were categorized as profound, 71 (40.3%) as severe, 36 (20.5%) as moderate,

and one (0.6%) as mild (Table 1). Comparison of GC and MD classifications revealed no

significant differences in the number of genes ultimately classified within each severity category

(36.9% vs. 38.6% profound, $p=0.74$; 39.6% vs. 40.3% severe, $p=0.51$; 23.9% vs. 20.5%

moderate, $p=0.44$; 2.3% vs. 0.6% mild, $p=0.18$, chi-squared test).

Disease Traits and Their Relationships to ACOG Severity Criteria

Disease traits most frequently cited by GCs and MDs across all genes as they applied the

severity algorithm were sensory impairment (85 genes), intellectual disability (70 genes), and

impaired mobility (67 genes) (Figure 4A). The disease traits that were least frequently cited

were immunodeficiency/cancer (12 genes) and mental illness (9 genes) (Figure 4A). The list of

genes and their assigned disease traits are provided in Supplementary Table 1.

To determine which of the diseases evaluated in this study met ACOG's four severity-related

criteria, MDs and GCs mapped the disease traits from the severity algorithm to the ACOG

criteria using validated scales and definitions (See Methods). The disease traits and their

mapping to each ACOG severity criteria are described in Table 2. The list of genes and their

ACOG severity criteria classification are provided in Supplementary Table 1.

The "detrimental effect on quality of life" criterion was the most frequently met ACOG criterion

(155 [88.1%] genes; 65 profound, 57 severe, and 33 moderate, Supplementary Figure 2).This

was followed by the "cause cognitive or physical impairment" criterion (97 [55.1%] genes; 54

profound, 31 severe, and 12 moderate, Supplementary Figure 2). Seventy-five (42.6%) genes

met the "onset early in life" criterion (56 profound, 17 severe, and 2 moderate, Supplementary

Figure 2). The least frequently met ACOG criterion was "require surgical or medical intervention"

(62 [35.2%] genes; 26 profound, 27 severe, and 9 moderate, Supplementary Figure 2). The

number of ACOG criteria met across all conditions was proportional to the categorized severity

of the gene: on average, profound genes met 2.8 ACOG severity criteria, severe genes met 1.9

criteria, moderate conditions met 1.6 traits, and the one mild condition met 0 criteria.

In total, 170 out of 176 genes (96.6%) met at least one of the four ACOG severity criteria, 129

genes (73.3%) met at least two ACOG severity criteria, 73 genes (41.5%) met at least 3 ACOG

severity criteria, and 17 genes (9.7%) met all four criteria (Figure 4B). Cystic fibrosis and spinal

muscular atrophy, two conditions recommended for panethnic screening by ACOG (11), met

one and four criteria, respectively (Supplementary Table 2). Of the remaining six genes that did

not meet at least one of the four ACOG severity criteria, one was classified as mild, two were

classified as moderate, and three were classified as severe (Figure 4B, Supplementary Table

1). The results of this disease trait-ACOG criteria mapping show that 170 of the 175 (97.1%)

genes that were classified as profound, severe, and moderate met at least one of the ACOG

severity criteria (Figure 4B, Supplementary Table 1).

Discussion

Here, we have demonstrated the application of a severity classification algorithm applied by

health care providers with expertise in pediatric and genetic disease to systematically classify

the severity of 176 genes on a commercially available ECS panel. In addition, heath care

providers operationalized the ACOG severity criteria via mapping of disease traits to the criteria,

thereby determining which of the genes analyzed in this study met the criteria.

Bringing Clarity to Severity Criteria in Guidelines

Guidelines stipulate disease severity as an important factor in the selection of conditions for

ECS panel inclusion yet describe severity in terms that are not easily interpreted. Our study

brings more clarity to ACOG's severity criteria; MDs and GCs who are experts in rare disease

unanimously agreed on the mapping of disease traits to the criteria. When evaluating 176 genes

disease traits, 170 met at least one of ACOG's severity criteria (Figure 4B), suggesting that they

are appropriate to consider for inclusion on ECS panels.

MDs and GCs mapping disease traits to ACOG's four severity criteria interpreted the criteria

based on definitions available in the literature, whenever possible, to avoid assumptions about

ACOG's intent. For example, ACOG's "detrimental effect on quality of life" criterion was

assessed using a definition of "quality of life" developed based on domains in the PedsQL, a

validated instrument for assessing quality of life in infants and children with chronic and acute

disease (8, 9). Social and family support, environment, and socioeconomic status may modify

detriments to the quality of life experienced by those with genetic disease, but were not included

in the evaluation of the ACOG criteria because they are not clearly accounted for by the

PedsQL instrument. Interpretation of the "onset early in life" criterion was based on the age limit

of adolescence as defined by the AAP (10). To unambiguously map "shortened lifespan" (the

trait assessed in the algorithm) to age of onset, only conditions that result in death before the

end of adolescence were considered to meet the criterion. Therefore, genetic conditions that

result in death during adulthood but that have an onset during or before adolescence, such as

familial dysautonomia and glycogen storage disease type 1a, did not meet the "onset early in

life" criterion, even though ACOG implicitly acknowledges the severity of such conditions by

suggesting both familial dysautonomia and glycogen storage disease type 1a as examples of

conditions to include on ECS panels (11). "Require surgical or medical intervention" was defined

as interventions delivered in the formal health care setting that are required to treat, delay, halt

the onset of, or lessen the severity of disease symptoms. For example, surgery to correct a

cardiac defect and treatment with chelating medications were considered to meet the ACOG

criterion. Palliative or supportive care, as well as interventions delivered outside the context of

the medical setting such as specialized early education for those with learning disabilities were

not considered to meet the criterion, though their benefits have been demonstrated (12).

While the majority of genes met at least one ACOG criteria, narrow interpretation of ACOG

criteria resulted in 8.5% of profound conditions and 28.0% of severe conditions, including cystic

fibrosis and Bloom syndrome, meeting only one ACOG criterion. Cystic fibrosis met the "require

surgical or medical intervention" criterion because treatments are available to lessen the

severity of disease symptoms. However, it does not usually cause death before the end of

adolescence (the trait corresponding to ACOG's "early onset in life" criterion), nor is it

characterized by disease traits that map to the other ACOG severity criteria. Similarly, Bloom

syndrome met the "detrimental effect on quality of life" criterion because it is associated with

high rates of cancer and immune deficiency leading to recurrent infections, but not with any of

the other traits defining ACOG's severity criteria. Given ACOG's recommendation for panethnic

cystic fibrosis carrier screening (11) and for Bloom syndrome carrier screening in Ashkenazi

Jewish individuals (13), it appears that ACOG supports carrier screening for conditions that

meet at least one of its four severity criteria.

Initial GC and MD discordance in ascribing disease traits to genes explains why five conditions

did not meet any ACOG criteria despite being categorized as severe or moderate. In order for a

trait to be mapped to ACOG criteria, all GCs and MDs assessing each gene had to initially

agree to the trait. However, the phenotypic spectrum caused by variable expressivity was a

common cause of initial discordant classification. For example, 21-hydroxylase congenital

adrenal hyperplasia (21-OH CAH) can present in a severe form characterized by life threatening

salt-wasting crises, or a less severe but more prevalent form characterized by physical

malformation (ambiguous external genitalia). This variability in presentation led some GCs and

MDs to initially assign disease traits differently for 21-OH CAH, and although consensus

severity categorization was reached, initial discordant traits precluded mapping to ACOG criteria

and resulted in 21-OH CAH not meeting any ACOG criteria. The severity algorithm applied here

takes variable expressivity into consideration and focuses on traits present in at least 25% of

individuals with mutations in a given gene, but the complexity of phenotypic presentation in

many rare diseases exemplifies one difficulty in interpreting ACOG criteria.

Utility of Screening for Moderate Severity Conditions by ECS

The term "moderate" as a descriptor of severity may connote to some that the disease does not

rise to a level of significance for a couple wanting to know their risk for having a pregnancy

affected by genetic disease. However, we found that 94.4% of moderate severity conditions met

at least one of ACOG's four severity criteria. As an example, *GJB2*, variants in which cause

non-syndromic hearing loss and deafness, was categorized as having moderate severity. Early

identification and interventions for individuals with hearing loss are critical; hearing loss

complicates childhood development in language, socialization, academic performance, and

most importantly human development and self-actualization (14-17). Interventions such as

cochlear implants can effectively avert these developmental delays (17). Previous studies have

also shown that couples find value in screening for moderate severity conditions. A majority of

couples identified by ECS to be at risk for pregnancies affected by moderate severity conditions

made reproductive and pregnancy management decisions for future family planning based on

knowledge of such risk (6, 7). In addition, patients preferred to receive ECS results on

conditions in all severity categories, including moderate, reporting that severity classifications

informed their choice (5).

Complexity of ECS panel design

ECS panel design is a complicated endeavor that must take into account a number of factors.

(18-21). ACOG suggests several criteria other than those related to severity that should guide

ECS panel design, including a carrier frequency of one in 100 or greater, a well-defined

phenotype, and the ability to diagnose the disease prenatally (2). Clear definitions of ACOG

criteria are needed to ensure consistency of ACOG criteria interpretations across different

laboratories. In addition to the in-depth analysis of the severity criteria provided by this study,

other criteria have been systematically evaluated. Ben-Shachar et al. (2019) and Guo and

Gregg (2019) concluded that a panel meeting the "carrier frequency of 1 in 100 or greater"

criterion would include approximately 40 conditions when that threshold is applied to any

ethnicity (19, 22). Balzotti et al (2020) examined the "well-defined phenotype" criterion by

applying the ClinGen framework for gene-disease association evidence (23) to more than 200

genes commonly included on commercial ECS panels, and found that the vast majority had the

highest level gene-disease association evidence (24). These studies, taken together with ours,

provide evidence-based interpretations of ACOG panel design criteria and act as guidance for

laboratories in the design of ECS offerings.

Limitations

This study has limitations that should be noted. First, the GC and MD participants were selected

to review the conditions because of their expertise in pediatrics and medical genetics, but their

application of the severity algorithm may not replicate application by other clinicians with similar

or different expertise. Second, the MDs were not blinded to the final GC classifications, so it is

possible that their classification was influenced by that of the GC pair. However, this paradigm

imitates clinical practice, in which GCs (or other providers) routinely present initial findings to

their clinical colleagues as the entire care team manages the patient. Third, genes were

assessed based on the available literature, which may skew toward more severe disease

presentations, particularly in the case of rare diseases. As understanding of phenotypes

evolves, severity classifications may change. And fourth, the mapping of disease traits to ACOG

criteria was not exhaustive, rather, it was limited to the traits in the algorithm. However, these

traits were themselves determined by genetics professionals with experience in rare disease

(4).

Conclusions

This study applied a systematic and transparent process to evaluate the severity of genes on a

commercially-available ECS panel by engaging with genetics providers with expertise in rare

disease. The severity algorithm applied in this study brings clarity to ACOG's severity criteria

and can be used consistently across laboratories when considering genes for inclusion on ECS

panels.

Acknowledgements

The authors thank Danielle Fanslow and Anna Gardiner for design and editorial assistance. This

study was funded by Myriad Women's Health.

References

1.	Haque IS, Lazarin GA, Kang HP, Evans EA, Goldberg JD, Wapner RJ. Modeled Fetal Risk of Genetic Diseases Identified by Expanded Carrier Screening. JAMA. 2016;316(7):734-42.

2.	ACOG Committee on Genetics. ACOG Committee Opinion No. 690: Carrier Screening in the Age of Genomic Medicine. 2017.

3.	Grody WW, Thompson BH, Gregg AR, Bean LH, Monaghan KG, Schneider A, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genetics in medicine : official journal of the American College of Medical Genetics. 2013;15(6):482-3.

4.	Lazarin GA, Hawthorne F, Collins NS, Platt EA, Evans EA, Haque IS. Systematic Classification of Disease Severity for Evaluation of Expanded Carrier Screening Panels. PloS one. 2014;9(12):e114391.

5.	Kraft SA, McMullen CK, Porter KM, Kauffman TL, Davis JV, Schneider JL, et al. Patient perspectives on the use of categories of conditions for decision making about genomic carrier screening results. American journal of medical genetics Part A. 2018;176(2):376-85.

6.	Johansen Taber KA, Beauchamp KA, Lazarin GA, Muzzey D, Arjunan A, Goldberg JD. Clinical utility of expanded carrier screening: results-guided actionability and outcomes. Genetics in medicine : official journal of the American College of Medical Genetics. 2019;21(5):1041-8.

7.	Ghiossi CE, Goldberg JD, Haque IS, Lazarin GA, Wong KK. Clinical Utility of Expanded Carrier Screening: Reproductive Behaviors of At-Risk Couples. J Genet Couns. 2018;27(3):616-25.

8.	Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800-12.

9.	Varni JW, Limbers CA, Neighbors K, Schulz K, Lieu JE, Heffer RW, et al. The PedsQL Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infants. Qual Life Res. 2011;20(1):45-55.

10.	Hardin AP, Hackell JM, Committee On P, Ambulatory M. Age Limit of Pediatrics. Pediatrics. 2017;140(3).

11.	American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 690: Carrier Screening in the Age of Genomic Medicine. Obstet Gynecol. 2017;129(3):e35-e40.

12.	Lopez-Rangel E, Mickelson ECR, Suzanne Lewis ME. The Value of a Genetic Diagnosis for Individuals with Intellectual Disabilities: Optimising Healthcare and Function Across the Lifespan. The British Journal of Development Disabilities. 2008;54(107):69-82.

13.	American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstet Gynecol. 2017;129(3):e41-e55.

14.	Moeller MP. Early intervention and language development in children who are deaf and hard of hearing. Pediatrics. 2000;106(3):E43.

15.	May-Mederake B. Early intervention and assessment of speech and language development in young children with cochlear implants. Int J Pediatr Otorhinolaryngol. 2012;76(7):939-46.

16.	Poonual W, Navacharoen N, Kangsanarak J, Namwongprom S. Outcome of Early Identification and Intervention on Infants with Hearing Loss Under Universal Hearing Screening Program. J Med Assoc Thai. 2017;100(2):197-206.

17.	Fulcher A, Purcell AA, Baker E, Munro N. Listen up: children with early identified hearing loss achieve age-appropriate speech/language outcomes by 3 years-of-age. Int J Pediatr Otorhinolaryngol. 2012;76(12):1785-94.

18.   Beauchamp KA, Muzzey D, Wong KK, Hogan GJ, Karimi K, Candille SI, et al.
Systematic design and comparison of expanded carrier screening panels. Genet Med.
2018;20(1):55-63.
19.   Ben-Shachar R, Svenson A, Goldberg JD, Muzzey D. A data-driven evaluation of the
size and content of expanded carrier screening panels. Genet Med. 2019;21(9):1931-9.
20.   Chokoshvili D, Vears D, Borry P. Expanded carrier screening for monogenic disorders:
where are we now? Prenat Diagn. 2018;38(1):59-66.
21.   Stevens B, Krstic N, Jones M, Murphy L, Hoskovec J. Finding Middle Ground in
Constructing a Clinically Useful Expanded Carrier Screening Panel. Obstet Gynecol.
2017;130(2):279-84.
22.   Guo MH, Gregg AR. Estimating yields of prenatal carrier screening and implications for
design of expanded carrier screening panels. Genet Med. 2019;21(9):1940-7.
23.   Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, DiStefano M, Dwight SS, et al.
Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework
Developed by the Clinical Genome Resource. Am J Hum Genet. 2017;100(6):895-906.
24.   Balzotti M, Meng L, Muzzey D, Johansen Taber K, Beauchamp KA, Team MGC, et al.
Clinical validity of expanded carrier screening: evaluating the gene-disease relationship in more
than 200 conditions Under Review:
https://wwwmedrxivorg/content/101101/2019121319014894v1. 2020.

Figure Legends

Figure 1. Severity classification algorithm evaluating specified disease traits (published by (4)). Each GC and MD used the algorithm to independently review and classify genes and their associated phenotype arising in at least 25% of individuals in the untreated state, as profound, severe, moderate, or mild.

Figure 2. Workflow of the severity classification process. Eight genetic counselors (GCs) were divided into four pairs; each pair was asked to review 44 genes. Once the GC pairs finished their initial review and resolved discordances, the classification process was then passed to the four medical geneticists (MDs) for review and final classification. Gene numbers in this figure correspond to the gene numbers in Table 1.

Figure 3. Concordance after initial gene severity classification. Concordance of initial severity classifications within each GC pair and in total among all GCs (A), and concordance of initial severity classification within each MD pair and in total among all MDs (B). Levels of discordance are indicated by color (pink: concordant, green: discordant by one level, blue: discordant by two levels, purple: not classified).

Figure 4. Genes classified by disease trait and ACOG severity criteria. (A) Genes classified by disease trait. (B) Genes classified by number of ACOG severity criteria met.

1. GC Classification

GC Pair 1 **Genes 1-44**	**GC Pair 2** **Genes 45-88**	**GC Pair 3** **Genes 89-132**	**GC Pair 4** **Genes 133-176**

- **Make initial independent classifications**

GC 1　GC 2　　GC 3　CG 4　　GC 5　CG 6　　GC 7　GC 8

- **Resolve discordances with partner**
- **Produce final GC classifications**

GC 1 and 2　　GC 3 and 4　　GC 5 and 6　　GC 7 and 8

2. MD Classification

MD Pair 1 **Genes 1-88**	**MD Pair 2** **Genes 89-176**

- **Review final GC classifications**
- **Make independent classifications**

MD 1　MD 2　　MD 3　MD 4

- **Resolve discordances with partner**
- **Resolve discordances with final GC classifications**
- **Produce final classifications**

MD 1 and 2　　MD 3 and 4

Table 1. Initial and final severity classifications between pairs of genetic counselors (GCs) and medical geneticists (MDs).

	Gene	Genetic Counselors				Medical Geneticists			
		Classification 1	Classification 2	Final Classification	Pair	Classification 1	Classification 2	Final Classification	Pair
1	HBB	Severe	Moderate	Severe	1	Moderate	Moderate	Moderate	1
2	DHCR7	Severe	Severe	Severe	1	Severe	Severe	Severe	1
3	PMM2	Profound	Profound	Profound	1	Profound	Profound	Profound	1
4	ACADS	Mild	Mild	Mild	1	Mild	Mild	Mild	1
5	LRPPRC	Profound	Profound	Profound	1	Profound	Profound	Profound	1
6	SLC26A2	Severe	Moderate	Moderate	1	Moderate	Moderate	Moderate	1
7	BTD	Moderate	Moderate	Moderate	1	Profound	Profound	Profound	1
8	MMAA	Profound	Severe	Severe	1	Profound	Profound	Profound	1
9	VPS13B	Severe	Severe	Severe	1	Severe	Severe	Severe	1
10	NPHS2	Severe	Severe	Severe	1	Severe	Severe	Severe	1
11	LIPA	Severe	Moderate	Severe	1	Severe	Severe	Severe	1
12	SMPD1	Profound	Profound	Profound	1	Profound	Profound	Profound	1
13	GLB1	Profound	Profound	Profound	1	Profound	Profound	Profound	1
14	FANCC	Moderate	Moderate	Moderate	1	Severe	Severe	Severe	1
15	GRHPR	Moderate	Moderate	Moderate	1	Moderate	Moderate	Moderate	1
16	IVD	Severe	Severe	Severe	1	Severe	Profound	Profound	1
17	MCOLN1	Severe	Severe	Severe	1	Severe	Severe	Severe	1
18	PEX12	Severe	Profound	Profound	1	Profound	Profound	Profound	1
19	AMT	Profound	Profound	Profound	1	Profound	Profound	Profound	1
20	TH	Severe	Severe	Severe	1	Severe	Severe	Severe	1
21	AGA	Severe	Severe	Severe	1	Severe	Severe	Severe	1
22	SLC12A6	Severe	Severe	Severe	1	Severe	Severe	Severe	1
23	SMN1	Severe	Severe	Severe	1	Severe	Severe	Severe	1
24	GAA	Severe	Severe	Severe	1	Severe	Severe	Severe	1
25	PKHD1	Profound	Severe	Profound	1	Severe	Severe	Severe	1
26	NR0B1	Severe	Mild	Mild	1	Moderate	Severe	Severe	1
27	BBS1	Severe	Severe	Severe	1	Severe	Severe	Severe	1
28	RMRP	Moderate	Moderate	Moderate	1	Moderate	Severe	Severe	1
29	PEX1	Severe	Profound	Profound	1	Profound	Profound	Profound	1
30	ALMS1	Severe	Moderate	Severe	1	Severe	Severe	Severe	1
31	ATM	Severe	Moderate	Severe	1	Severe	Severe	Severe	1
32	BLM	Severe	Moderate	Moderate	1	Severe	Severe	Severe	1
33	ASPA	Profound	Profound	Profound	1	Profound	Profound	Profound	1
34	PEX7	Profound	Profound	Profound	1	Profound	Profound	Profound	1
35	MKS1	Profound	Profound	Profound	1	Profound	Profound	Profound	1
36	SGCG	Moderate	Moderate	Moderate	1	Moderate	Moderate	Moderate	1
37	POMGNT1	Profound	Profound	Profound	1	Profound	Profound	Profound	1

38	EVC	Moderate	Moderate	Moderate	1	Moderate	Moderate	Moderate	1
39	PTS	Moderate	Severe	Severe	1	Severe	Severe	Severe	1
40	ZFYVE26	Severe	Severe	Severe	1	Severe	Severe	Severe	1
41	GNPTG	Moderate	Moderate	Moderate	1	Severe	Severe	Severe	1
42	GALK1	Mild	Moderate	Moderate	1	Moderate	Moderate	Moderate	1
43	CPT1A	Severe	Moderate	Severe	1	Moderate	Severe	Severe	1
44	IL2RG	Profound	Profound	Profound	1	Severe	Severe	Severe	1
45	CFTR	Moderate	Severe	Severe	2	Moderate	Severe	Severe	1
46	GLA	Moderate	Severe	Severe	2	Moderate	Severe	Severe	1
47	RS1	Moderate	Moderate	Moderate	2	Moderate	Moderate	Moderate	1
48	ASL	Profound	Profound	Profound	2	Profound	Profound	Profound	1
49	ATP7A	Profound	Profound	Profound	2	Profound	Profound	Profound	1
50	MYO7A	Moderate	Moderate	Moderate	2	Moderate	Moderate	Moderate	1
51	ALPL	Moderate	Moderate	Moderate	2	Not Classified	Moderate	Moderate	1
52	AGXT	Mild	Moderate	Moderate	2	Severe	Severe	Severe	1
53	GCDH	Severe	Moderate	Moderate	2	Severe	Moderate	Moderate	1
54	AGL	Mild	Moderate	Moderate	2	Moderate	Moderate	Moderate	1
55	LAMB3	Severe	Moderate	Severe	2	Severe	Severe	Severe	1
56	ALG6	Severe	Severe	Severe	2	Severe	Severe	Severe	1
57	ABCC8	Mild	Profound	Profound	2	Severe	Severe	Severe	1
58	MAN2B1	Severe	Severe	Severe	2	Severe	Severe	Severe	1
59	GNE	Moderate	Moderate	Moderate	2	Moderate	Moderate	Moderate	1
60	RTEL1	Moderate	Profound	Profound	2	Profound	Profound	Profound	1
61	HSD17B4	Moderate	Profound	Profound	2	Profound	Profound	Profound	1
62	SGCB	Moderate	Moderate	Moderate	2	Moderate	Moderate	Moderate	1
63	PEX6	Profound	Profound	Profound	2	Profound	Profound	Profound	1
64	HLCS	Severe	Profound	Profound	2	Profound	Profound	Profound	1
65	CLN5	Profound	Profound	Profound	2	Profound	Profound	Profound	1
66	KCNJ11	Mild	Severe	Severe	2	Not Classified	Profound	Profound	1
67	CYP21A2	Severe	Mild	Severe	2	Not Classified	Severe	Severe	1
68	USH2A	Moderate	Moderate	Moderate	2	Moderate	Moderate	Moderate	1
69	ALDOB	Severe	Moderate	Moderate	2	Not Classified	Severe	Severe	1
70	MTM1	Severe	Severe	Severe	2	Severe	Severe	Severe	1
71	OTC	Profound	Severe	Profound	2	Not Classified	Profound	Profound	1
72	CLN3	Profound	Severe	Profound	2	Severe	Severe	Severe	1
73	NPC1	Severe	Profound	Profound	2	Profound	Profound	Profound	1
74	DYSF	Moderate	Moderate	Moderate	2	Moderate	Moderate	Moderate	1
75	PEX2	Profound	Profound	Profound	2	Profound	Profound	Profound	1
76	TGM1	Mild	Moderate	Moderate	2	Moderate	Moderate	Moderate	1
77	FAH	Severe	Severe	Severe	2	Severe	Profound	Profound	1
78	SACS	Moderate	Severe	Severe	2	Severe	Severe	Severe	1
79	SLC17A5	Profound	Severe	Severe	2	Severe	Severe	Severe	1

80	FKTN	Profound	Profound	Profound	2	Profound	Profound	Profound	1
81	BCKDHB	Profound	Profound	Profound	2	Severe	Profound	Profound	1
82	STAR	Profound	Severe	Severe	2	Severe	Severe	Severe	1
83	ALDH3A2	Severe	Severe	Severe	2	Severe	Severe	Severe	1
84	XPA	Moderate	Severe	Severe	2	Severe	Severe	Severe	1
85	MLC1	Severe	Severe	Severe	2	Severe	Severe	Severe	1
86	PEX10	Profound	Profound	Profound	2	Profound	Profound	Profound	1
87	LAMA3	Severe	Moderate	Severe	2	Severe	Severe	Severe	1
88	OPA3	Moderate	Severe	Moderate	2	Moderate	Moderate	Moderate	1
89	FMR1	Severe	Severe	Severe	3	Severe	Severe	Severe	2
90	MEFV	Moderate	Moderate	Moderate	3	Moderate	Moderate	Moderate	2
91	ATP7B	Moderate	Moderate	Moderate	3	Moderate	Moderate	Moderate	2
92	GALT	Profound	Profound	Profound	3	Profound	Severe	Profound	2
93	CPT2	Profound	Profound	Profound	3	Profound	Severe	Profound	2
94	HEXA	Profound	Profound	Profound	3	Profound	Profound	Profound	2
95	ARSA	Profound	Profound	Profound	3	Profound	Profound	Profound	2
96	BCS1L	Profound	Profound	Profound	3	Profound	Profound	Profound	2
97	HEXB	Profound	Profound	Profound	3	Profound	Profound	Profound	2
98	AIRE	Moderate	Moderate	Moderate	3	Moderate	Moderate	Moderate	2
99	PCCB	Profound	Profound	Profound	3	Profound	Profound	Profound	2
100	TPP1	Profound	Profound	Profound	3	Profound	Severe	Profound	2
101	NBN	Profound	Severe	Severe	3	Severe	Severe	Severe	2
102	NAGLU	Profound	Severe	Profound	3	Profound	Profound	Profound	2
103	DLD	Profound	Profound	Profound	3	Profound	Severe	Profound	2
104	SLC37A4	Moderate	Severe	Severe	3	Severe	Severe	Severe	2
105	COL4A4	Moderate	Severe	Severe	3	Severe	Severe	Severe	2
106	ADA	Profound	Severe	Profound	3	Profound	Severe	Profound	2
107	BCKDHA	Profound	Profound	Profound	3	Profound	Profound	Profound	2
108	MPI	Profound	Moderate	Severe	3	Severe	Severe	Severe	2
109	NPC2	Profound	Severe	Profound	3	Profound	Profound	Profound	2
110	TAT	Severe	Severe	Severe	3	Severe	Severe	Severe	2
111	PAH	Severe	Severe	Severe	3	Severe	Moderate	Severe	2
112	ACADM	Profound	Profound	Profound	3	Profound	Profound	Profound	2
113	GBA	Profound	Moderate	Severe	3	Severe	Severe	Severe	2
114	CAPN3	Moderate	Moderate	Moderate	3	Moderate	Moderate	Moderate	2
115	HOGA1	Mild	Moderate	Mild	3	Mild	Moderate	Moderate	2
116	NEB	Severe	Moderate	Severe	3	Severe	Severe	Severe	2
117	LAMA2	Severe	Moderate	Moderate	3	Moderate	Moderate	Moderate	2
118	IKBKAP	Severe	Severe	Severe	3	Severe	Moderate	Severe	2
119	HYLS1	Severe	Profound	Profound	3	Profound	Profound	Profound	2
120	FKRP	Profound	Moderate	Profound	3	Profound	Profound	Profound	2
121	G6PC	Moderate	Severe	Severe	3	Severe	Severe	Severe	2

122	SGCA	Moderate	Moderate	Moderate	3	Moderate	Moderate	Moderate	2
123	ASS1	Profound	Profound	Profound	3	Profound	Profound	Profound	2
124	PCDH15	Moderate	Moderate	Moderate	3	Moderate	Mild	Moderate	2
125	CYP11B1	Moderate	Moderate	Moderate	3	Moderate	Moderate	Moderate	2
126	BBS2	Severe	Severe	Severe	3	Severe	Severe	Severe	2
127	MMAB	Profound	Profound	Profound	3	Profound	Profound	Profound	2
128	XPC	Severe	Severe	Severe	3	Severe	Severe	Severe	2
129	TMEM216	Profound	Severe	Profound	3	Profound	Profound	Profound	2
130	ARG1	Severe	Severe	Severe	3	Severe	Severe	Severe	2
131	CLN8	Profound	Profound	Profound	3	Profound	Severe	Profound	2
132	SGCD	Moderate	Moderate	Moderate	3	Moderate	Moderate	Moderate	2
133	DMD	Severe	Moderate	Severe	4	Severe	Severe	Severe	2
134	COL4A5	Moderate	Moderate	Moderate	4	Moderate	Severe	Moderate	2
135	IDS	Severe	Moderate	Severe	4	Profound	Severe	Profound	2
136	ABCD1	Profound	Profound	Profound	4	Profound	Profound	Profound	2
137	MMACHC	Profound	Profound	Profound	4	Profound	Severe	Profound	2
138	ACADVL	Moderate	Severe	Moderate	4	Severe	Moderate	Severe	2
139	GALC	Profound	Profound	Profound	4	Profound	Profound	Profound	2
140	CTNS	Moderate	Severe	Severe	4	Severe	Severe	Severe	2
141	NPHS1	Moderate	Severe	Severe	4	Profound	Severe	Profound	2
142	CYP27A1	Severe	Severe	Severe	4	Severe	Moderate	Severe	2
143	GNPTAB	Profound	Severe	Profound	4	Profound	Profound	Profound	2
144	MUT	Profound	Severe	Profound	4	Profound	Severe	Profound	2
145	TCIRG1	Profound	Severe	Profound	4	Profound	Profound	Profound	2
146	PROP1	Moderate	Moderate	Moderate	4	Moderate	Moderate	Moderate	2
147	EVC2	Severe	Moderate	Severe	4	Moderate	Severe	Severe	2
148	CLRN1	Mild	Mild	Mild	4	Moderate	Moderate	Moderate	2
149	PCCA	Severe	Profound	Profound	4	Profound	Profound	Profound	2
150	HGSNAT	Severe	Severe	Severe	4	Profound	Severe	Profound	2
151	MESP2	Severe	Moderate	Severe	4	Moderate	Severe	Severe	2
152	LAMC2	Severe	Severe	Severe	4	Severe	Moderate	Severe	2
153	CPS1	Profound	Profound	Profound	4	Profound	Profound	Profound	2
154	PC	Profound	Profound	Profound	4	Profound	Profound	Profound	2
155	GJB2	Moderate	Moderate	Moderate	4	Moderate	Moderate	Moderate	2
156	HBA1/HBA2	Severe	Moderate	Moderate	4	Severe	Moderate	Moderate	2
157	SLC26A4	Moderate	Moderate	Moderate	4	Moderate	Moderate	Moderate	2
158	CBS	Severe	Severe	Severe	4	Severe	Severe	Severe	2
159	IDUA	Profound	Profound	Profound	4	Profound	Profound	Profound	2
160	FANCA	Moderate	Severe	Severe	4	Severe	Severe	Severe	2
161	SLC22A5	Moderate	Severe	Moderate	4	Profound	Moderate	Profound	2
162	SGSH	Severe	Profound	Profound	4	Profound	Profound	Profound	2
163	COL4A3	Severe	Moderate	Moderate	4	Moderate	Mild	Moderate	2

164	BBS10	Severe	Severe	Severe	4	Severe	Severe	Severe	2
165	HADHA	Severe	Severe	Severe	4	Severe	Severe	Severe	2
166	ERCC6	Profound	Profound	Profound	4	Profound	Profound	Profound	2
167	PPT1	Profound	Profound	Profound	4	Profound	Severe	Profound	2
168	DBT	Profound	Profound	Profound	4	Profound	Severe	Profound	2
169	GLDC	Profound	Profound	Profound	4	Profound	Profound	Profound	2
170	BBS12	Severe	Severe	Severe	4	Severe	Severe	Severe	2
171	USH1C	Moderate	Moderate	Moderate	4	Moderate	Moderate	Moderate	2
172	TTPA	Moderate	Severe	Severe	4	Moderate	Severe	Severe	2
173	ERCC8	Profound	Profound	Profound	4	Profound	Profound	Profound	2
174	HMGCL	Severe	Profound	Severe	4	Profound	Severe	Profound	2
175	CTSK	Moderate	Moderate	Moderate	4	Moderate	Moderate	Moderate	2
176	CLN6	Profound	Profound	Profound	4	Profound	Severe	Profound	2

Table 2. Mapping of the algorithm's disease traits to ACOG severity criteria.

ACOG Severity Criteria	Have a detrimental effect on quality of life	Cause cognitive or physical impairment	Have an onset early in life	Require surgical or medical intervention
Algorithm Disease Traits	Intellectual disability Impaired mobility Internal physical malformation Sensory impairment Dysmorphic features Mental illness Immunodeficiency/ cancer	Intellectual disability Impaired mobility	Shortened lifespan: infancy/ childhood/adolescence	Availability of treatment